Cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 154, Issue 5, 1996, Pages 1229-1256

  Davis, Pamela B ^a,b   Drumm, Mitchell ^a   Konstan, Michael W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CHLORIDE; CHLORIDE CHANNEL; CORTICOSTEROID; FISH OIL; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PROTEINASE INHIBITOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; GENE MUTATION; GENE STRUCTURE; GENE THERAPY; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; IMMUNOTHERAPY; INFLAMMATION; ION TRANSPORT; LUNG TRANSPLANTATION; PANCREAS INSUFFICIENCY; PATHOGENESIS; PHENOTYPE; POSTURAL DRAINAGE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SWEAT TEST;

EID: 0029823833     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.154.5.8912731     Document Type: Review

References (380)

1. Wood, R. E., T. F. Boat, and C. F. Doershuk. 1976. State of the art: cystic fibrosis. Am. Rev. Respir. Dis. 113:833-878.
2. Quinton, P. M. 1986. Missing C1 conductance in cystic fibrosis. Am. J. Physiol. 251:C649-C652.
3. Knowles, M. R., J. Gatzy, and R. C. Boucher. 1981. Increased bioelectric potential differences across respiratory epithelial in cystic fibrosis. N. Engl. J. Med. 305:1489-1498.
4. Knowles, M. R., M. J. Stutts, A. Spock, N. Fischer, J. T. Gatzy, and R. C. Boucher. 1983. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 221:1067-1070.
5. Tsui, L. C., M. Buchwald, D. Barker, J. C. Braman, R. R. Knowlton, J. W. Schumm, H. Eiberg, J. Mohr, D. Kennedy, N. Plavsic, M. Zsiga, D. Markiewicz, G. Akots, V. Brown, C. Helms, T. Gravins, T. Parker, K. Rediker, and H. Donis-Keller. 1985. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230:1054-1057.
6. Rommens, J. M., M. C. Iannuzzi, B. Kerem, M. L. Drumm, G. Melmer, M. Dean, R. Rozmahel, J. L. Cole, D. Kennedy, N. Hidaka, M. Zsiga, M. Buchwald, J. R. Riordan, L.-C. Tsui, and F. S. Collins. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059-1065.
7. Riordan, J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.-L. Chou, M. L. Drumm, M. C. Iannuzzi, F. S. Collins, and L.-C. Tsui. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073.
8. Kerem, B., J. M. Rommens, J. A. Buchanan, D. Markiewicz, T. K. Cox, A. Chakravarti, M. Buchwald, and L.-C. Tsui. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080.
9. Cystic Fibrosis Foundation. 1995. Patient Registry 1994 Annual Data Report. Cystic Fibrosis Foundation, Bethesda, Maryland.
10. FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr. 122:1-9.
11. Davis, P. B., and P. A. di Sant'Agnese. 1984. Diagnosis and treatment of cystic fibrosis: an update. Chest 85:802-809.
12. Davis, P. B., V. S. Hubbard, and P. A. di Sant'Agnese. 1980. Low sweat electrolytes in patients with cystic fibrosis. Am. J. Med. 69:643-646.
13. Chillon, M., T. Casals, B. Mercier, L. Bassas, W. Lissens, S. Silber, M. C. Romey, J. Ruiz Romero, C. Verlingue, and M. Claustres. 1995. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332:1475-1480.
14. Birnkrant, D. J., and R. C. Stern. 1991. Sweat testing in the 90s. Am. J. Asthma Allergy Pediatr. 4:194-198.
15. Davis, P. B., S. Del Rio, J. A. Muntz, and L. Dieckman. 1983. Sweat chloride concentration in adults with pulmonary diseases. Am. Rev. Respir. Dis. 128:34-37.
16. Kulczycki, L., and V. Schauf. 1974. Cystic fibrosis in blacks in Washington DC: incidence and characteristics. Am. J. Dis. Child. 127:64-67.
17. Wright, S. W., and N. E. Morton. 1968. Genetic studies on cystic fibrosis in Hawaii. Am. J. Hum. Genet. 20:157-169.
18. Scambler, P., O. Oyen, B. Wainwright, M. Farrall, H. Y. Law, X. Estivill, M. Sandberg, R. Williamson, and T. Jahnsen. 1987. Exclusion of catalytic and regulatory subunits of cAMP-dependent protein kinase as candidate genes for the defect causing cystic fibrosis. Am. J. Hum. Genet. 41:925-932.
19. Poustka, A. M., H. Lehrach, R. Williamson, and G. Bates. 1988. A long-range restriction map encompassing the cystic fibrosis locus and its closely linked genetic markers. Genomics 2:337-345.
20. Drumm, M. L., C. L. Smith, M. Dean, J. L. Cole, M. C. Iannuzzi, and F. S. Collins. 1988. Physical mapping of the cystic fibrosis region by pulsed field gel electrophoresis. Genomics 2:346-354.
21. Rommens, J. M., S. Zengerling Lentes, B. Kerem, O. Melmer, M. Buchwald, and L. C. Tsui. 1989. Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis. Am. J. Hum. Genet. 45:932-941.
22. Collins, F. S., M. L. Drumm, J. L. Cole, W. K. Lockwood, G. F. Vande Woude, and M. C. Iannuzzi. 1987. Construction of a general human chromosome jumping library, with application to cystic fibrosis. Science 235:1046-1049.
23. Rich, D. P., M. P. Anderson, R. J. Gregory, S. H. Cheng, S. Paul, D. Jefferson, J. D. McCann, K. W. Klinger, A. E. Smith, and M. J. Welsh. 1990. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347:358-363.
24. Drumm, M. L., H. A. Pope, W. H. Cliff, J. M. Rommens, S. A. Marvin, L. C. Tsui, F. S. Collins, R. A. Frizzell, and J. M. Wilson. 1990. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 62:1227-1233.
25. Yoshimura, K., H. Nakamura, B. C. Trapnell, W. Dalemans, A. Pavirani, J. P. Lecocq, and R. G. Crystal. 1991. The cystic fibrosis gene has a "housekeeping"-type promoter and is expressed at low levels in cells of epithelial origin. J. Biol. Chem. 266:9140-9144.
26. Bargon, J., B. C. Trapnell, K. Yoshimura, W. Dalemans, A. Pavirani, J. P. Lecocq, and R. G. Crystal. 1992. Expression of the cystic fibrosis transmembrane conductance regulator gene can be regulated by protein kinase C. J. Biol. Chem. 267:16056-16060.
27. Chou, J. L., R. Rozmahel, and L. C. Tsui. 1991. Characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene. J. Biol. Chem. 266:24471-24476.
28. Koh, J., T. J. Sferra, and F. S. Collins. 1993. Characterization of the cystic fibrosis transmembrane conductance regulator promoter region. Chromatin context and tissue-specificity. J. Biol. Chem. 268: 15912-15921.
29. Breuer, W., N. Kartner, J. R. Riordan, and Z. I. Cabantchik. 1992. Induction of expression of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 267:10465-10469.
30. Chu, C. S., B. C. Trapnell, J. J. Murtagh, Jr., J. Moss, W. Dalemans, S. Jallat, A. Mercenier, A. Pavirani, J. P. Lecocq, G. R. Cutting, W. B. Guggino, and R. G. Crystal. 1991. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. E.M.B.O. J. 10:1355-1363.
31. Delaney, S. J., D. P. Rich, S. A. Thomson, M. R. Margrave, P. K. Lovelock, M. J. Welsh, and B. J. Wainwright. 1993. Cystic fibrosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat. Genet. 4:426-431.
32. Hamosh, A., B. J. Rosenstein, and G. R. Cutting. 1992. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum. Mol. Genet. 1:542-544.
33. Highsmith, W. E., L. H. Burch, Z. Zhou, J. C. Olsen, T. F. Boat, A. Spock, J. D. Gorvoy, L. Quittell, K. J. Friedman, L. M. Silverman, R. C. Boucher, and M. R. Knowles. 1994. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N. Engl. J. Med. 331:974-980.
34. Cheng, S. H., R. J. Gregory, J. Marshall, S. Paul, D. W. Souza, G. A. White, C. R. O'Riordan, and A. E. Smith. 1990. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827-834.
35. Denning, G. M., M. P. Anderson, J. F. Amara, J. Marshall, A. E. Smith, and M. J. Welsh. 1992. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761-764.
36. Sato, S., C. L. Ward, M. E. Krouse, J. J. Wine, and R. R. Kopito. 1996. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271:635-638.
37. Li, C., M. Ramjeesingh, E. Reyes, T. Jensen, X. Chang, J. M. Rommens, and C. E. Bear. 1993. The cystic fibrosis mutation (ΔF508) does not influence the chloride channel activity of CFTR. Nat. Genet. 3:311-316.
38. Drumm, M. L., D. J. Wilkinson, L. S. Smit, R. T. Worrell, T. V. Strong, R. A. Frizzell, D. C. Dawson, and F. S. Collins. 1991. Chloride conductance expressed by DF508 and other mutant CFTRs in Xenopus oocytes. Science 254:1797-1799.
39. Sheppard, D. N., L. S. Ostedgaard, M. C. Winter, and M. J. Welsh, 1995. Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. E.M.B.O. J. 14: 876-883.
40. Can, K.-H., H. J. Veeze, A. M. W. Van denOuweland, D. J. J. Halley, H. Scheffer, A. Van derHout, S. E. Overbeek, J. C. DeJongste, W. Bakker, and H. G. M. Heijerman. 1995. A cystic fibrosis mutation associated with mild lung disease. N. Engl. J. Med. 333:95-99.
41. Ward, C. L., S. Omura, and R. R. Kopito. 1995. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121-127.
42. Jensen, T. J., M. A. Loo, S. Pind, D. B. Williams, A. L. Goldberg, and J. R. Riordan. 1995. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129-135.
43. Yang, Y., S. Janich, J. A. Cohn, and J. M. Wilson. 1993. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. U.S.A. 90:9480-9484.
44. Pind, S., J. R. Riordan, and D. B. Williams. 1994. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269:12784-12788.
45. - channels with altered pore properties. Nature 362:160-164.
46. Smit, L. S., T. V. Strong, D. J. Wilkinson, M. Macek, M. K. Mansoura, D. L. K. Wood, J. L. Cole, G. R. Cutting, J. A. Cohn, D. C. Dawson, and F. S. Collins. 1995. Missense mutation (G480C) in the CFTR gene associated with protein mislocalization but normal channel activity. Hum. Mol. Genet. 4:264-275.
47. Welsh, M. J., and A. E. Smith. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254.
48. Kristidis, P., D. Bozon, M. Corey, D. Markiewicz, J. Rommens, L. C. Tsui, and P. Durie. 1992. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 50: 1178-1184.
49. Gaskin, K., D. Gurwitz, P. Durie, M. Corey, H. Levison, and G. Forstner. 1982. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J. Pediatr. 100:857-862.
50. Chu, C. S., B. C. Trapnell, S. Curristin, G. R. Cutting, and R. G. Crystal. 1993. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat. Genet. 3:151-156.
51. Kiesewetter, S., M. Macek, Jr., C. Davis, S. M. Curristin, C. S. Chu, C. Graham, A. E. Shrimpton, S. M. Cashman, L. C. Tsui, J. Mickle, J. Amos, W. E. Highsmith, A. Shuber, D. R. Witt, R. G. Crystal, and G. R. Cutting. 1993. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat. Genet. 5:274-278.
52. Anguiano, A., R. D. Oates, J. A. Amos, M. Dean, B. Gerrard, C. Steward, T. A. Maher, M. B. White, and A. Milunsky. 1992. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. J.A.M.A. 267:1794-1797.
53. Gabriel, S. E., K. N. Brigman, B. H. Koller, R. C. Boucher, and M. J. Stutts. 1994. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266:107-109.
54. Cuthbert, A. W., J. Halstead, R. Ratcliff, W. H. Colledge, and M. J. Evans. 1995. The genetic advantage hypothesis in cystic fibrosis heterozygotes: a murine study. J. Physiol. (Lond.) 482:449-454.
55. American Society of Human Genetics. 1992. Statement on cystic fibrosis carrier screening. Am. J. Hum. Genet. 51:1443-1444.
56. Lemna, W. K., G. L. Feldman, B. Kerem, S. D. Fernbach, E. P. Zevkovich, W. O'Brien, J. R. Riordan, F. S. Collins, L. C. Tsui, and A. L. Beaudet. 1990. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N. Engl. J. Med. 322: 291-296.
57. Ober, C., L. A. Lester, C. Mott, C. Billstrand, A. Lemke, K. van der Ven, S. Marcus, J. Kraut, J. Lloyd Still, and C. Booth. 1992. Ethnic heterogeneity and cystic fibrosis transmembrane regulator (CFTR) mutation frequencies in Chicago-area CF families. Am. J. Hum. Genet. 51:1344-1348.
58. Coutelle, C., C. Williams, A. Handyside, K. Hardy, R. Winston, and R. Williamson. 1989. Genetic analysis of DNA from single human oocytes: a model for preimplantation diagnosis of cystic fibrosis. B.M.J. 299:22-24.
59. Fugger, E. F., A. Maddalena, and J. D. Schulman. 1993. Results of retroactive testing of human semen donors for cystic fibrosis and human immunodeficiency virus by polymerase chain reaction. Hum. Reprod. 8:1435-1437.
60. Bear, C. C., H. Li, N. Kartner, R. J. Bridges, T. J. Jensen, M. Ramjeesingh, and J. R. Riordan. 1992. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR) Cell 68:809-819.
61. Cunningham, S. A., R. T. Worrell, D. J. Benos, and R. A. Frizzell. 1992. cAMP-stimulated ion currents in Xenopus oocytes expressing CFTR cRNA. Am. J. Physiol. 262:C783-C788.
62. Gregory, R. J., S. H. Cheng, D. P. Rich, J. Marshall, S. Paul, K. Hehir, L. Ostedgaard, K. W. Klinger, M. J. Welsh, and A. E. Smith. 1990. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature 347:382-386.
63. Tilly, B. C., M. C. Winter, L. S. Ostedgaard, C. O'Riordan, A. E. Smith, and M. J. Welsh. 1992. Cyclic AMP-dependent protein kinase activation of cystic fibrosis transmembrane conductance regulator chloride channels in planar lipid bilayers. J. Biol. Chem. 267:9470-9473.
64. Higgins, C. F. 1992. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:67-113.
65. Chang, X.-B., Y.-X. Hou, T. J. Jensen, and J. R. Riordan. 1994. Mapping of cystic fibrosis transmembrane conductance regulator membrane topology by glycosylation site insertion. J. Biol. Chem. 269: 18572-18575.
66. Anderson, M. P., R. J. Gregory, S. Thompson, D. W. Souza, S. Paul, R. C. Mulligan, A. E. Smith, and M. J. Welsh. 1991. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253:202-205.
67. McDonough, S., N. Davidson, H. A. Lester, and N. A. McCarty. 1994. Novel pore-lining residues in CFTR that govern permeation and open-channel block. Neuron 13:623-634.
68. Akabas, M. H., C. Kaufmann, T. A. Cook, and P. Archdeacon. 1994. Amino acid residues lining the chloride channel of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269:14865-14868.
69. Oblatt-Montal, M., G. L. Reddy, T. Iwamoto, J. M. Tomich, and M. Montai. 1994. Identification of an ion channel-forming motif in the primary structure of CFTR, the cystic fibrosis chloride channel. Proc. Natl. Acad. Sci. U.S.A. 91:1495-1499.
70. Carroll, T. P., M. M. Morales, S. B. Fulmer, S. S. Allen, T. R. Flotte, G. R. Cutting, and W. B. Guggino. 1995. Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 270:11941-11946.
71. - channel. Cell 76:1091-1098.
72. - conductance. F.E.B.S. Lett. 374:312-316.
73. Anderson, M. P., H. A. Berger, D. P. Rich, R. J. Gregory, A. E. Smith, and M. J. Welsh. 1991. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 67:775-784.
74. Ko, Y. H., and P. L. Pedersen. 1995. The first nucleotide binding fold of the cystic fibrosis transmembrane conductance regulator can function as an active ATPase. J. Biol. Chem. 270:22093-22096.
75. Smit, L. S., D. J. Wilkinson, M. K. Mansoura, F. S. Collins, and D. C. Dawson. 1993. Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator. Proc. Natl. Acad. Sci. U.S.A. 90:9963-9967.
76. Gunderson, K. L., and R. R. Kopito. 1994. Effects of pyrophosphate and nucleotide analogs suggest a role for ATP hydrolysis in cystic fibrosis transmembrane regulator channel gating. J. Biol. Chem. 269:19349-19353.
77. Rich, D. P., R. J. Gregory, M. P. Anderson, P. Manavalan, A. E. Smith, and M. J. Welsh. 1991. Effect of deleting the R domain on CFTR-generated chloride channels. Science 253:205-207.
78. Ma, J., J. E. Tasch, T. Tao, J. Zhao, J. Xie, M. L. Drumm, and P. B. Davis. 1995. Phosphorylation-dependent block of CFTR chloride channel by exogenous R domain protein. J. Biol. Chem. 271: 7351-7356.
79. - channel by negative charge in the R domain. J. Biol. Chem. 268:20259-20267.
80. Cheng, S. H., D. P. Rich, J. Marshall, et al. 1991. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66:1027-1036.
81. Chang, X.-B., J. A. Tabcharani, Y.-X. Hou, T. J. Jensen, N. Kartner, N. Alon, J. W. Hanrahan, and J. R. Riordan. 1993. Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. J. Biol. Chem. 268: 11304-11311.
82. Seibert, F. S., J. A. Tabcharani, X.-B. Chang, A. M. Dulhanty, C. Mathews, J. W. Hanrahan, and J. R. Riordan. 1995. cAMP-dependent protein kinase-mediated phosphorylation of cystic fibrosis transmembrane conductance regulator residue Ser-753 and its role in channel activation. J. Biol. Chem. 270:2158-2162.
83. Dechecchi, M. C., A. Tamanini, G. Berton, and G. Cabrini. 1993. Protein kinase C activates chloride conductance in C127 cells stably expressing the cystic fibrosis gene. J. Biol. Chem. 268:11321-11325.
84. - channel in CHO cells stably expressing the cystic fibrosis gene. Nature 352:628-631.
85. Xie, J., M. L. Drumm, J. Ma, and P. B. Davis. 1995. Intracellular loop between TM4 and TM5 of CFTR is involved in regulation of chloride channel conductance. J. Biol. Chem. 270:28084-28091.
86. Schwiebert, E. M., M. E. Egan, T.-H. Hwang, S. B. Fulmer, S. S. Allen, G. R. Cutting, and W. B. Guggino. 1995. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 81:1063-1073.
87. Reisin, I. L., A. G. Prat, E. H. Abraham, J. F. Amara, R. J. Gregory, D. A. Ausiello, and H. F. Cantiello. 1994. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J. Biol. Chem. 269:20584-20591.
88. Hasegawa, H., W. Skach, O. Baker, M. C. Calayag, V. Lingappa, and A. S. Verkman. 1992. A multifunctional aqueous channel formed by CFTR. Science 258:1477-1479.
89. Frizzell, R. A., G. Rechkemmer, and R. L. Shoemaker. 1986. Altered regulation of airway epithelial cell chloride channels in cystic fibrosis. Science 233:558-560.
90. Li, M., J. D. McCann, C. M. Liedtke, A. C. Nairn, P. Greengard, and M. J. Welsh. 1988. Cyclic AMP-dependent protein kinase opens chloride channels in normal but not cystic fibrosis airway epithelium. Nature 331:358-360.
91. Guggino, W. B. 1993. Outwardly rectifying chloride channels and CF: a divorce and remarriage. J. Bioenerg. Biomembr. 25:27-35.
92. - channels by protein kinase A corrected by insertion of CFTR. Nature 358:581-584.
93. Gabriel, S. E., L. L. Clarke, R. C. Boucher, and M. Jackson Stutts. 1993. CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 363:263-266.
94. Schwiebert, E. M., T. Flotte, G. R. Cutting, and W. B. Guggino. 1994. Both CFTR and outwardly rectifying chloride channels contribute to cAMP-stimulated whole cell chloride currents. Am. J. Physiol. 266:C1464-C1477.
95. - channels in normal and cystic fibrosis airway epithelial cells by extracellular ATP. Proc. Natl. Acad. Sci. U.S.A. 89:1621-1625.
96. Stutts, M. J., J. G. Fitz, A. M. Paradiso, and R. C. Boucher. 1994. Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP. Am. J. Physiol. 267:C1442-C1451.
97. Knowles, M. R., L. L. Clarke, and R. C. Boucher. 1991. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325:533-538.
98. Clarke, L. L., B. R. Grubb, J. R. Yankaskas, C. U. Cotton, A. McKenzie, and R. C. Boucher. 1994. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in CFTR (-/-)mice. Proc. Natl. Acad. Sci. U.S.A. 91:479-483.
99. Clarke, L. L., K. A. Burns, J.-Y. Bayle, R. C. Boucher, and M. R. Van Scott. 1992. Sodium- and chloride-conductive pathways in cultured mouse tracheal epithelium. Am. J. Physiol. 263:L519-L525.
100. + permeability in cystic fibrosis human primary cell cultures. J. Physiol. (Lond.) 405:77-103.
101. + transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activation. J. Clin. Invest. 78:1245-1252.
102. + channel subunits in normal and cystic fibrosis airways. Am. J. Physiol. 269:C511-C518.
103. Stutts, M. J., C. M. Canessa, J. C. Olsen, M. Hamrick, J. A. Cohn, B. C. Rossier, and R. C. Boucher. 1995. CFTR as a cAMP-dependent regulator of sodium channels. Science 269:847-850.
104. Knowles, M. R., N. L. Church, W. E. Waltner, J. R. Yankaskas, P. Gilligan, M. King, L. J. Edwards, R. W. Helms, and R. C. Boucher. 1990. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med. 332:1189-1194.
105. Tomkiewicz, R. P., E. M. App, J. G. Zayas, O. Ramirez, N. Church, R. C. Boucher, M. R. Knowles, and M. King. 1993. Amiloride inhalation therapy in cystic fibrosis: influence on ion content, hydration, and rheology of sputum. Am. Rev. Respir. Dis. 148:1002-1007.
106. Schwiebert, E. M., N. Kizer, D. C. Gruenert, and B. A. Stanton. 1992. GTP-binding proteins inhibit cAMP activation of chloride channels in cystic fibrosis airway epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 89:10623-10627.
107. Kelley, T. J., L. Al-Nakkash, and M. L. Drumm. 1995. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 13:657-664.
108. Sarkadi, B., D. Bauzon, W. R. Huckle, H. S. Earp, A. Berry, H. Suchindran, E. M. Price, J. C. Olsen, R. C. Boucher, and G. A. Scarborough. 1992. Biochemical characterization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis epithelial cells. J. Biol. Chem. 267:2087-2095.
109. Cotton, C. U., M. J. Stutts, M. R. Knowles, J. T. Gatzy, and R. C. Boucher. 1987. Abnormal apical cell membrane in cystic fibrosis respiratory epithelium. J. Clin. Invest. 79:80-85.
110. Denning, G. M., L. S. Ostedgaard, and M. J. Welsh. 1992. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J. Cell Biol. 118:551-559.
111. Bradbury, N. A., T. Jiling, G. Berta, E. J. Sorscher, R. J. Bridges, and K. L. Kirk. 1992. Regulation of plasma membrane recycling by CFTR. Science 256:530-532.
112. Barasch, J., B. Kiss, A. Prince, L. Saiman, D. Gruenert, and Q. AlAwqati. 1991. Defective acidification of intracellular organelles in cystic fibrosis. Nature 352:70-73.
113. Al-Awqati, Q., J. Barasch, and D. Landry. 1992. Chloride channels of intracellular organelles and their potential role in cystic fibrosis. J. Exp. Biol. 172:245-266.
114. Barasch, J., and Q. Al-Awqati. 1993. Defective acidification of the biosynthetic pathway in cystic fibrosis. J. Cell Sci. 106 (Suppl. 17): 229-233.
115. - movements in human colonie epithelial cells (HT29-Cl, 16E). Biochem. J. 304: 675-678.
116. Weyer, P., J. Barasch, Q. Al Awqati, D. A. Ausiello, and D. Brown. 1995. Immunolocalization of two sialyltransferases is altered in polarized LLC-PK1 epithelial cells expressing ΔF508 CFTR. Pediatr. Pulmonol. Suppl. 10:238.
117. Gibson, L. E., and R. E. Cooke. 1959. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics 23:545-549.
118. Wine, J. J. 1988. The heterozygote phenotype in cystic fibrosis. In G. Mastellax and P. M. Quinton, editors. Cellular and Molecular Basis of Cystic Fibrosis. San Francisco Press, San Francisco. 33-46.
119. diSant'Agnese, P. A., R. C. Darling, G. A. Perera, and E. Shea. 1953. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics 12:549-563.
120. Beckerman, R. C., and L. M. Taussig. 1979. Hypoelectrolytemia and metabolic alkalosis in infants with cystic fibrosis. Pediatrics 63: 580-583.
121. Kopito, L. E., H. J. Kosasky, and H. Shwachman. 1973. Water and electrolytes in cervical mucus from patients with CF. Fertil. Steril. 24:512-516.
122. Penketh, A. R. L., A. Wise, M. B. Mearns, M. E. Hodson, and J. C. Batten. 1987. Cystic fibrosis in adolescents and adults. Thorax 42:526-532.
123. Cohen, L. F., P. A. di Sant'Agnese, and J. Friedlander. 1980. Cystic fibrosis and pregnancy: a national survey. Lancet 2:842-844.
124. Canny, G. J., M. Corey, R. A. Livingstone, S. Carpenter, L. Green, and H. Levison. 1991. Pregnancy and cystic fibrosis. Obstet. Gynecol. 77:850-853.
125. Stern, R. C. 1993. CF and the reproductive system. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 381-400.
126. Yeung, W., K. Hardy, L. Quittell, and S. Fiel. 1987. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am. J. Med. 82:871-879.
127. Taussig, L. M., C. C. Lobeck, P. A. diSant'Agnese, D. R. Ackerman, and J. Kattwinkel. 1972. Fertility in males with cystic fibrosis. N. Engl. J. Med. 287:586-589.
128. Silber, S. J., T. Ord, J. Balmeceda, P. Patrizio, and R. H. Asch. 1990. Congenital absence of the vas deferens: the fertilizing capacity of human epididymal sperm. N. Engl. J. Med. 323:1788-1792.
129. Stern, R. C. 1993. CF and the gastrointestinal tract. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 401-434.
130. Matseshe, J. W., V. L. W. Go, and E. P. DiMagno. 1977. Meconium ileus equivalent complicating cystic fibrosis in postneonatal children and young adults. Gastroenterology 72:732-736.
131. Snouwaert, J. N., K. K. Brigman, A. M. Latour, N. N. Malouf, R. C. Boucher, O. Smithies, and B. H. Koller. 1992. An animal model for cystic fibrosis made by gene targeting. Science 257:1083-1088.
132. Zhou, L., C. R. Dey, S. E. Wert, M. D. Duvall, R. A. Frizzell, and J. A. Whitsett. 1994. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266:1705-1708.
133. Tomashefski, J. F., C. R. Abramowsky, and B. B. Dahms. 1993. The pathology of cystic fibrosis. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 435-590.
134. Rose, M. C. 1988. Epithelial mucous glycoproteins and cystic fibrosis. Horm. Metab. Res. 20:601-608.
135. diSant'Agnese, P. A., and P. B. Davis. 1979. Cystic fibrosis in adults: 75 cases and a review of 232 cases in the literature. Am. J. Med. 66:121-132.
136. Caniano, D. A., and B. L. Beaver. 1987. Meconium ileus: a fifteen-year experience with forty-two neonates. Surgery 102:699-703.
137. Rubinstein, S., R. Moss, and N. Lewiston. 1986. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics 78:473-479.
138. Cleghorn, G. J., D. A. Stringer, G. G. Forstner, and P. R. Durie. 1986. Treatment of distal intestinal obstruction in cystic fibrosis with a balanced intestinal lavage solution. Lancet 1:8-11.
139. Craig, J. M., H. Haddad, and H. Shwachman. 1957. The pathological changes in the liver in cystic fibrosis of the pancreas. Ant. J. Dis. Child. 93:357-369.
140. Stern, R. C., D. P. Stevens, T. F. Boat, C. F. Doershuk, R. J. Izant, Jr., and L. W. Matthews. 1976. Symptomatic hepatic disease in cystic fibrosis: incidence, course, and outcome of portal systemic shunting. Gastroenterology 70:645-649.
141. Cox, K. L., R. E. Ward, T. L. Furguiele, R. A. Cannon, K. D. Sanders, and G. Kurland. 1987. Orthotopic liver transplantation in patients with cystic fibrosis. Pediatrics 80:571-574.
142. Stern, R. C., F. C. Rothstein, and C. F. Doershuk. 1986. Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 5:35-40.
143. Colombo, C., K. D. R. Setchell, M. Podda, A. Crosignani, A. Roda, L. Curcio, M. Ronchi, and A. Giunta. 1990. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J. Pediatr. 117:482-489.
144. Cotting, J., M. J. Lentze, and J. Reichen. 1990. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 31:918-921.
145. Galabert, C., J. C. Montel, D. Lengrand, A. Lecuire, C. Sotta, C. Figarella, and J. P. Chazalette. 1992. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J. Pediatr. 121:138-141.
146. Hadorn, B., P. G. Johansen, and C. M. Anderson. 1968. Pancreozymin secretin test of exocrine pancreatic function in cystic fibrosis and the significance of the result for the pathogenesis of the disease. Can. Med. Assoc. J. 98:377-385.
147. Kopelman, H., P. Durie, K. Gaskin, Z. Weizman, and G. Forstner. 1985. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N. Engl. J. Med. 312:329-334.
148. Kopelman, H., M. Corey, K. Gaskin, P. Durie, Z. Weizman, and G. Forstner. 1988. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology 95:349-355.
149. Cotton, C. U., and P. B. Davis. 1993. The pancreas in cystic fibrosis. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 161-192.
150. Atlas, A. B., S. R. Orenstein, and D. M. Orenstein. 1992. Pancreatitis in young children with cystic fibrosis. J. Pediatr. 120:756-759.
151. Tomezski, J. L., V. A. Stallings, D. A. Kawchak, J. E. Goin, G. Diamond, and T. F. Scanlin. 1994. Energy expenditure and genotype of children with cystic fibrosis. Pediatr. Res. 35:451-460.
152. Arvanitakis, C., and A. R. Cooke. 1978. Diagnostic tests of exocrine pancreatic function and disease. Gastroenterology 74:932-948.
153. Lapey, A., J. Kattwinkel, P. A. diSant Agnese, and L. Lester. 1974. Steatorrhea and azotorrhea and their relation to growth and nutrition in adolescents and young adults with cystic fibrosis. J. Pediatr. 84:328-334.
154. Nousia-Arvanitakis, S., C. Arvanitakis, N. Desai, and N. J. Greenberger. 1978. Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid. J. Pediatr. 92:734-737.
155. Bellentani, S., A. Grisendi, M. Rinaldi, P. Bertolani, G. Costa, M. Agostini, G. Mastella, G. Balli, and F. Manenti. 1984. BT-PABA test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared. Eur. J. Pediatr. 143:145-148.
156. Zentler-Munro, P. L., D. R. Fine, J. C. Batten, and T. C. Northfield. 1985. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 26:892-901.
157. Smyth, R. L., D. Van Velzen, A. R. Smyth, D. A. Lloyd, and D. P. Heaf. 1994. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 343:35-86.
158. Ramsey, B. W., P. M. Farrell, P. Pencharz, and The Consensus Committee. 1992. Nutritional assessment and management in cystic fibrosis: a consensus report. Am. J. Clin. Nutr. 55:108-116.
159. Byard, P. J. 1989. Relationship between clinical parameters and linear growth in children with cystic fibrosis. Am. J. Hum. Biol. 1: 719-725.
160. Wilfond, B. S., P. M. Farrell, A. Laxova, and E. Mischler. 1994. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis: implications for neonatal screening. Clin. Pediatr. 33:2-7.
161. Underwood, B. A., and C. R. Denning. 1972. Blood and liver concentrations of vitamin A and E in children with cystic fibrosis of the pancreas. Pediatr. Res. 6:26.
162. Reiter, E. O., S. M. Brugman, J. W. Pike, M. Pitt, S. Dokoh, M. R. Haussler, R. S. Gerstle, and L. M. Taussig. 1985. Vitamin D metabolites in adolescents and young adults with cystic fibrosis: effects of sun and season. J. Pediatr. 106:21-26.
163. Tortstenson, O. L., F. B. Humphrey, J. R. Edson, and W. J. Warwick. 1970. Cystic fibrosis presenting with severe hemorrhage due to vitamin K malabsorption. Pediatrics 45:857.
164. Farrell, P. M., J. G. Bieri, J. F. Fratantoni, R. E. Wood, and P. A. di Sant'Agnese. 1977. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. J. Clin. Invest. 60:233-241.
165. Nasr, S. Z., M. H. O'Leary, and C. Hillermeier. 1993. Correction of
166. Lippe, B. M., M. A. Sperling, and R. R. Dooley. 1977. Pancreatic alpha and beta cell functions in cystic fibrosis. J. Pediatr. 90:751-755.
167. Handwerger, S., J. Roth, P. Gorden, P. diSant'Agnese, D. F. Carpenter, and G. Peter. 1969. Glucose intolerance in cystic fibrosis. N. Engl. J. Med. 281:451-461.
168. Ramsey, B., and M. A. Richardson. 1992. Impact of sinusitis in cystic fibrosis. J. Allergy Clin. Immunol. 90:547-552.
169. Sharma, G. D., C. F. Doershuk, and R. C. Stern. 1994. Erosion of the wall of the frontal sinus caused by mucopyocele in cystic fibrosis. J. Pediatr. 124:745-747.
170. Shapiro, E. D., G. J. Milmoe, E. R. Wald, J. B. Rodnan, and A. Bowen. 1982. Bacteriology of the maxillary sinuses in patients with cystic fibrosis. J. Infect. Dis. 146:589-593.
171. Moss, R. B., and V. V. King. 1995. Management of sinusitis in cystic fibrosis by endoscopie surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Arch. Otolaryngol. Head Neck Surg. 121:566-572.
172. Davidson, T. M., C. Murphy, M. Mitchell, C. Smith, and M. Light. 1995. Management of chronic sinusitis in cystic fibrosis. Laryngoscope 105:354-358.
173. Stern, R. C., T. F. Boat, R. E. Wood, L. W. Matthews, and C. F. Doershuk. 1982. Treatment and prognosis of nasal polyps in cystic fibrosis. Am. J. Dis. Child. 136:1067-1070.
174. Shwachman, H., L. L. Kulczychi, H. L. Mueller, and C. G. Flake. 1962. Nasal polyposis in patients with cystic fibrosis. Pediatrics 30: 389-401.
175. di Sant'Agnese, P. A. 1965. Nasal polyposis and cystic fibrosis. J.A.M.A. 191:685.
176. Rulon, J. T., H. A. Brown, and G. B. Logan. 1963. Nasal polyps and cystic fibrosis of the pancreas. Arch. Otolaryngol. 78:192-199.
177. Oppenheimer, E. H., and B. J. Rosenstein. 1979. Differential pathology of nasal polyps in cystic fibrosis and atopy. Lab. Invest. 40: 445-449.
178. Crockett, D. M., T. J. McGill, G. B. Healy, E. M. Friedman, and L. J. Salkeld. 1987. Nasal and paranasal sinus surgery in children with cystic fibrosis. Ann. Otol. Rhinol. Laryngol. 96:367-372.
179. Sturgess, J., and J. Imrie. 1982. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am. J. Pathol. 106:303-311.
180. McCray, P. B., Jr., C. L. Wohlford-Lenane, and J. M. Snyder. 1992. Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization. J. Clin. Invest. 90:619-625.
181. McGrath, S. A., A. Basu, and P. L. Zeitlin. 1993. Cystic fibrosis gene and protein expression during fetal lung development. Am. J. Respir. Cell Mol. Biol. 8:201-208.
182. May, J. R., N. C. Herrick, and D. Thompson. 1972. Bacterial infection in cystic fibrosis. Arch. Dis. Child. 47:908.
183. Hoiby, N. 1975. Prevalence of mucoid strains of Pseudomonas aeruginosa in bacteriological specimens from patients with other diseases. Acta Pathol. Microbiol. Scand. 83:549-552.
184. Reynolds, H. Y., P. A. di Sant'Agnese, and C. H. Zierdt. 1976. Mucoid Pseudomonas aeruginosa: a sign of cystic fibrosis in young adults with chronic pulmonary disease? J.A.M.A. 236:2190-2192.
185. Tosi, M. F., H. Zakem, and M. Berger. 1990. Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J. Clin. Invest. 86:300-308.
186. Berger, M., R. U. Sorensen, M. F. Tosi, D. G. Dearborn, and G. Doring. 1989. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infecled lung in cystic fibrosis. J. Clin. Invest. 84:1302-1313.
187. Fick, R. B., Jr., G. P. Nagel, S. U. Squier, R. E. Wood, J. B. L. Gee, and H. Y. Reynolds. 1984. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J. Clin. Invest. 74:236-248.
188. Konstan, M. W., and M. Berger. 1993. Infection and inflammation of the lung in cystic fibrosis. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 219-276.
189. Smith, J. J., P. H. Karp, and M. J. Welsh. 1994. Defective fluid transport by cystic fibrosis airway epithelia. J. Clin. Invest. 93:1307-1311.
190. Jiang, C., W. E. Finkbeiner, J. H. Widdicombe, P. B. McCray, Jr., and S. S. Miller. 1993. Altered fluid transport across airway epithelium in cystic fibrosis. Science 262:424-427.
191. Rooklin, A. R., S. J. McGeady, D. O. Mikaelian, R. Z. Soriano, and H. C. Mansmann. 1980. The immotile cilia syndrome: a cause of recurrent pulmonary disease in children. Pediatrics 66:526-531.
192. Ron, H.-D. 1979. Kartagener's syndrome and the syndrome of immotile cilia. Hum. Genet. 46:249-261.
193. Miller, R. D., and M. B. Divertie. 1972. Kartagener's syndrome. Chest 62:130-135.
194. Wood, R. E., A. Wanner, J. Hirch, and P. M. Farrell. 1975. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am. Rev. Respir. Dis. 111:733-738.
195. Yeates, D. B., J. M. Sturgess, S. R. Kahn, H. Levison, and N. Aspin. 1976. Mucociliary transport in trachea of patients with cystic fibrosis. Arch. Dis. Child. 51:28-33.
196. Regnis, J. A., M. Robinson, D. L. Bailey, P. Cook, P. Hooper, H.-K. Chan, I. Gonda, G. Bautovich, and P. T. P. Bye. 1994. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 150:66-71.
197. Nakamura, H., K. Yoshimura, N. G. McElvaney, and R. G. Crystal. 1992. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest. 89:1478-1484.
198. Bruce, M. C., L. Poncz, J. D. Klinger, R. C. Stern, J. F. Tomashefski, Jr., and D. G. Dearborn. 1985. Biochemical and pathologie evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am. Rev. Respir. Dis. 132:529-535.
199. Sommerhoff, C. P., J. A. Nadel, C. B. Basbaum, and G. H. Caughey. 1990. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J. Clin. Invest. 85:682-689.
200. Saiman, L., G. Cacalano, D. Gruenert, and A. Prince. 1992. Comparison of adherence of P. aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect. Immun. 60:2808-2814.
201. Zar, H., L. Saiman, L. Quittell, and A. Prince. 1995. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J. Pediatr. 126:230-233.
202. Saiman, L., and A. Prince. 1993. Pseudomonas aeruginosa pili bind to asialoGM1, which is increased on the surface of cystic fibrosis epithelial cells. J. Clin. Invest. 92:1875-1880.
203. Demko, C. A., P. J. Byard, and P. B. Davis. 1995. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 48:1041-1049.
204. Henry, R. L., C. M. Mellis, and L. Petrovic. 1992. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12:158-161.
205. Cacalano, G., M. Kays, L. Saiman, and A. Prince. 1992. Production of the Pseudomonas aeruginosa neuraminidase is increased under hyperosmolar conditions and is regulated by genes involved in alginate expression. J. Clin. Invest. 89:1866-1874.
206. Chan, R., J. S. Lam, K. Lam, and J. W. Costerton. 1984. Influence of culture conditions on expression of mucoid mode of growth of Pseudomonas aeruginosa. J. Clin. Microbiol. 19:8-16.
207. Macone, A. B., G. B. Pier, J. E. Pennington, W. J. Matthews, and D. A. Goldman. 1981. Mucoid Escherichia coli in cystic fibrosis. N. Engl. J. Med. 304:1445-1449.
208. Armstrong, D. S., K. Grimwood, R. Carzino, J. B. Carlin, A. Olinsky, and P. D. Phelan. 1995. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. B.M.J. 310: 1571-1572.
209. Khan, T. Z., J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D. W. Riches. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-1082.
210. Bonfield, T. L., M. W. Konstan, P. Burfeind, J. R. Panuska, J. B. Hilliard, and M. Berger. 1995. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 13:257-261.
211. Beardsmore, C. S., E. Bar-Yishay, C. Maayan, Y. Yahav, D. Katznelson, and S. Godfrey. 1988. Lung function in infants with cystic fibrosis. Thorax 43:545-551.
212. Kerem, E., J. Reisman, M. Corey, L. Bentur, G. Canny, and H. Levison. 1992. Wheezing in infants with cystic fibrosis: clinical course, pulmonary function and survival analysis. Pediatrics 90:703-706.
213. Tepper, R. S., G. L. Montgomery, V. Ackerman, and H. Eigen. 1993. Longitudinal evaluation of pulmonary function in infants and very young children with cystic fibrosis. Pediatr. Pulmonol. 16:96-100.
214. Mohon, R. T., J. S. Wagener, S. H. Abman, W. K. Seltzer, and F. J. Accurso. 1993. Relationship of genotype to early pulmonary function in infants with cystic fibrosis identified through neonatal screening. J. Pediatr. 122:550-555.
215. Cooper, D. M., E. Doron, A. L. Mansell, A. C. Bryan, and H. Levison. 1974. The relative sensitivity of closing volume in children with asthma and cystic fibrosis. Am. Rev. Respir. Dis. 109:519.
216. Zapletal, A., E. K. Motoyama, L. E. Gibson, and A. Bouhuys. 1971. Pulmonary mechanics in asthma and cystic fibrosis. Pediatrics 48:64.
217. Landau, L. I., and P. D. Phelan. 1973. The spectrum of cystic fibrosis. Am. Rev. Respir. Dis. 108:593-602.
218. Kerem, E., J. Reisman, M. Corey, G. Canny, and H. Levison. 1992. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 326:1187-1191.
219. Pederson, S. S., N. Hoiby, F. Espersen, and C. Koch. 1992. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47:6-13.
220. Lewin, L. O., P. J. Byard, and P. B. Davis. 1995. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J. Clin. Epidemiol. 43:125-131.
221. Lorin, M. I., and C. R. Denning. 1971. Evaluation of postural drainage by measurement of sputum volume and consistency. Am. J. Phys. Med. 50:215-219.
222. Rossman, C. M., R. Waldes, D. Sampson, and M. T. Newhouse. 1982. Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. Am. Rev. Respir. Dis. 126:131-135.
223. Desmond, K. J., F. W. Schwenk, E. Thomas, P. H. Beaudry, and A. L. Coates. 1983. Immediate and long-tern effects of chest physiotherapy in patients with cystic fibrosis. J. Pediatr. 103:538-542.
224. Reisman, J. J., B. Rivington-Law, M. Corey, J. Marcotte, E. Wannamaker, D. Harcourt, and H. Levison. 1988. Role of conventional physiotherapy in cystic fibrosis. J. Pediatr. 113:632-636.
225. Hardy, K. A. 1994. A review of airway clearance: new techniques, indications, and recommendations. Respir. Care 39:440-445.
226. Thomas, J., D. J. Cook, and D. Brooks. 1995. Chest physical therapy management of patient with cystic fibrosis: a meta-analysis. Am. J. Respir. Crit. Care Med. 151:846-850.
227. Kraemer, R., C. Zumbuhl, A. Rudeberg, M. J. Lentze, and J. Chevaillier. 1986. "Autogenic drainage" bei patienten mit zystischer fibrose. Pediatr. Prax. 33:223-232.
228. Schoini, M. H. 1989. Autogenic drainage: a modern approach to physiotherapy in cystic fibrosis. J. R. Soc. Med. 82(Suppl. 16):32-37.
229. Pryor, J. A., B. A. Webber, M. E. Hudson, and J. C. Batten. 1979. Evaluation of the forced expiration technique as an adjunct to postural drainage in treatment of cystic fibrosis. B.M.J. 2:417-418.
230. Pryor, J. 1991. The forced expiratory technique. In J. Pryor, editor. Respiratory Care. Churchill Livingstone, London. 79-100.
231. Lindemann, H. 1992. Zum Stellenwert der physiotherapie mit dem VRP 1-Desitin ("Flutter"). Pneumologie 46:626-630.
232. Konstan, M. W., R. C. Stern, and C. F. Doershuk. 1994. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J. Pediatr. 124:689-693.
233. Warwick, W. J., and L. G. Hansen. 1991. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr. Pulmonol. 11:265-271.
234. Tonnesen, P., and S. Stovring. 1984. Positive expiratory pressure (PEP) as lung physiotherapy in cystic fibrosis: a pilot study. Eur. J. Respir. Dis. 65:419-422.
235. Oberwaldner, B., J. C. Evans, and M. S. Zach. 1986. Forced expirations against a variable resistance: a new chest physiotherapy method in cystic fibrosis. Pediatr. Pulmonol. 2:358-367.
236. Van Asperen, P. P., L. Jackson, P. Hennessy, and J. Brown. 1987. Comparison of a positive expiratory pressure (PEP) mask with postural drainage in patients with cystic fibrosis. Aust. Paediatr. J. 23:283-284.
237. Steen, H. J., A. O. B. Redmond, D. O'Neill, and F. Beattie. 1991. Evaluation of the PEP mask in cystic fibrosis. Ada Paediatr. Scand. 80:51-56.
238. Natale, J. E., J. Pfeifle, and D. N. Homnick. 1994. Comparison of intrapulmonary percussive ventilation and chest physiotherapy. Chest 105:1789-1793.
239. Landau, L. I., and P. D. Phelan. 1973. The variable effect of a bronchodilating agent on pulmonary function in cystic fibrosis. J. Pediatr. 82:863-868.
240. Larsen, G. L., R. J. Barron, E. K. Cotton, and J. G. Brooks. 1979. A comparative study of inhaled atropine sulfate and isoproterenol hydrochloride in cystic fibrosis. Am. Rev. Respir. Dis. 119:399-407.
241. Kattan, M., A. Mansell, H. Levison, M. Corey, and I. R. B. Krastins. 1980. Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. Thorax 35:531-535.
242. Ormerol, L. P., R. A. Thomson, C. M. Anderson, and D. E. Stabelforth. 1980. Reversible airway obstruction in cystic fibrosis. Thorax 35:768-772.
243. Svenonius, E., M. J. Arborelius, R. Kautto, R. Kornfalt, and T. Lindberg. 1980. Lung function in cystic fibrosis. Respiration 40:226-232.
244. Hordvik, N. L., P. Konig, D. Morris, C. Kreutz, and G. J. Barbero. 1985. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am. Rev. Respir. Dis. 131:889-893.
245. Zach, M. S., B. Oberwaldner, G. Forche, and G. Polgar. 1985. Bronchodilators increase airway instability in cystic fibrosis. Am. Rev. Respir. Dis. 131:537-543.
246. Hiatt, P., H. Eigen, P. Yu, and R. S. Tepper. 1988. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am. Rev. Respir. Dis. 137:119-122.
247. Pattishall, E. N. 1990. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr. Pulmonol. 9:80-85.
248. König, P., D. Gayer, G. J. Barbero, and J. Shaffer. 1995. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr. Pulmonol. 20:205-214.
249. Salomon, A., J. A. Herchfus, and M. S. Segal. 1954. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann. Allergy 12:71-79.
250. Raskin, P. 1968. Bronchospasm after inhalation of pancreatic dornase. Am. Rev. Respir. Dis. 98:697-698.
251. Shak, S., D. J. Capon, R. Hellmiss, S. A. Marsters, and C. L. Baker. 1990. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. U.S.A. 87:9188-9192.
252. Hubbard, R. C., N. G. McElvaney, P. Birrer, S. Shak, W. W. Robinson, C. Jolley, M. Wu, M. S. Chernick, and R. G. Crystal. 1992. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N. Engl. J. Med. 326:812-815.
253. Aitken, M. L., W. Burke, G. McDonald, S. Shak, A. B. Montgomery, and A. Smith. 1992. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1 study. J.A.M.A. 267:1947-1951.
254. Ramsey, B. W., S. J. Astley, M. L. Aitken, W. Burke, A. A. Colin, H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, I. R. Harwood, D. V. Schidlow, R. W. Wilmott, M. E. Wohl, L. J. Meyerson, S. Shak, H. Fuchs, and A. L. Smith. 1993. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am. Rev. Respir. Dis. 148:145-151.
255. Fuchs, H. J., D. S. Borowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, B. W. Ramsey, B. J. Rosenstein, A. L. Smith, and M. E. Wohl for the Pulmozyme Study Group. 1994. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331:637-642.
256. Vasconcellos, C. A., P. G. Allen, M. E. Wohl, J. M. Drazen, P. A. Janmey, and T. P. Stossel. 1994. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263:969-971.
257. Rubin, B. K., A. P. Kater, T. Dian, O. E. Ramirez, R. P. Tomkiewicz, and A. L. Goldstein. 1995. Effects of thymosin β4 on cystic fibrosis sputum. Pediatr. Pulmonol. Suppl. 12:234.
258. Andersen, D. H. 1949. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics 3:406-417.
259. Shwachman, H., P. Catzel, P. R. Patterson, and M. Stoppelman. 1954. Mucoviscidosis: an evaluation of continuous and prolonged antibiotic therapy. Am. J. Dis. Child. 88:380-382.
260. Matthews, L. W., C. F. Doershuk, M. Wise, G. Eddy, H. Nudelman, and S. Spector. 1964. A therapeutic regimen for patients with cystic fibrosis. J. Pediatr. 65:558-575.
261. Hoiby, N., B. Friis, K. Jensen, C. Koch, N. E. Moller, S. Stovring, and M. Szaff. 1982. Antimicrobial chemotherapy in cystic fibrosis patients. Ada Paediatr. Scand. Suppl. 301:75-100.
262. Jensen, T., S. S. Pedersen, N. Hoiby, C. Koch, and E. W. Flensborg. 1989. Use of antibiotics in cystic fibrosis. The Danish approach. Antibiot. Chemother. 42:237-246.
263. Marks, M. I. 1989. Antibiotic therapy for bronchopulmonary infections in cystic fibrosis. The American approach. Antibiot. Chemother. 42:229-236.
264. Stern, R. C., T. F. Boat, C. F. Doershuk, A. S. Tucker, F. P. Primiano, Jr., and L. W. Matthews. 1976. Course of cystic fibrosis in 95 patients. J. Pediatr. 89:406-411.
265. Szaff, M., N. Hoiby, and E. W. Flensborg. 1983. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Ada Paediatr. Scand. 72:651-657.
266. Gilligan, P. H., P. A. Gage, L. M. Bradshaw, D. V. Schidlow, and B. T. DeCicco. 1985. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J. Clin. Microbiol. 22:5-8.
267. Doern, G. V., and B. Brodgen-Torres. 1992. Optimum use of selective plated media in primary processing of respiratory tract specimens from patients with cystic fibrosis. J. Clin. Microbiol. 30: 2740-2742.
268. deGroot, R., and A. L. Smith. 1987. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significances. Clin. Pharmacokinet. 13:228-253.
269. Klinger, J. D., and S. C. Aronoff. 1985. In vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. J. Antimicrob. Chemother. 15:679-684.
270. Pedersen, S. S., T. Jensen, and E. F. Hvidberg. 1987. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J. Antimicrob. Chemother. 20:575-583.
271. Jensen, T., S. S. Pedersen, C. H. Nielsen, N. Hoiby, and C. Koch. 1987. The efficacy and safety of ciprofloxacin and ofloxacin in the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis. J. Antimicrob. Chemother. 20:585-594.
272. Bender, S. W., A. Dalhoff, P. M. Shah, R. Strehl, and H. G. Posselt. 1986. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 14:17-21.
273. Goldfarb, J., G. P. Wormser, M. A. Inchiosa, G. Guideri, M. Diaz, R. Gandhi, C. Goltzman, and A. V. Mascia. 1986. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J. Clin. Pharmacol. 26:222-226.
274. LeBel, M., M. B. Bergeron, F. Vallee, C. Fiset, G. Chasse, P. Bigonesse, and G. Rivard. 1986. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob. Agents Chemother. 30:260-266.
275. Reed, M. D., R. C. Stern, C. M. Myers, T. S. Yamashita, and J. L. Blumer. 1988. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J. Clin. Pharmacol. 28: 691-699.
276. Smith, A. L. 1986. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. J. Pediatr. 108:866-870.
277. Goldfarb, J., R. C. Stern, M. D. Reed, T. S. Yamashita, C. M. Myers, and J. L. Blumer. 1987. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am. J. Med. 82:174-179.
278. Shalit, I., H. R. Stutman, M. I. Marks, S. A. Chartrand, and B. C. Human. 1987. Randomized study of two dosing regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patient with cystic fibrosis. Am. J. Med. 82:189-195.
279. Scully, B. E., M. Nakatomi, C. Ores, S. Davidson, and H. C. Neu. 1987. Ciprofloxacin therapy in cystic fibrosis. Am. J. Med. 82: 196-201.
280. Rubio, T. T. 1987. Ciprofloxacin: comparative data in cystic fibrosis. Am. J. Med. 82:185-188.
281. Hodson, M. E., C. M. Roberts, R. J. A. Butland, M. J. Smith, and J. C. Batten. 1987. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1:235-237.
282. Bosso, J. A. 1989. Use of ciprofloxacin in cystic fibrosis patients. Am. J. Med. 87:S123-S127.
283. Carswell, F., C. Ward, D. A. Cook, and D. C. E. Speller. 1987. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br. J. Dis. Chest. 81:356.
284. MacLusky, I. B., R. Gold, M. Corey, and H. Levison. 1989. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Pulmonol. 7: 42-48.
285. Steinkamp, G., B. Tummler, M. Gappa, A. Albus, J. Potel, G. Doring, and H. von der Hardt. 1989. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr. Pulmonol. 6:91-98.
286. Smith, A. L., B. W. Ramsey, D. L. Hedges, B. Hack, J. Williams-Warren, A. Weber, E. J. Gore, and G. J. Redding. 1989. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pulmonol. 7:265-271.
287. Littlewood, J. M., M. G. Miller, A. T. Ghoneim, and C. H. Ramsden. 1985. Nebulized colomycin for early pseudomonas colonization in cystic fibrosis. Lancet 2:865-867.
288. Jensen, T., S. S. Pedersen, S. Garne, C. Heilmann, N. Hoiby, and C. Koch. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 19:831-838.
289. Valerius, N. H., C. Koch, and N. Hoiby. 1991. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 338:725-726.
290. Hodson, M. E., A. R. L. Penketh, and J. C. Batten. 1981. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 2:1137-1139.
291. Ramsey, B. W., H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, I. R. Harwood, R. M. Kravitz, D. V. Schidlow, R. W. Wilmott, S. J. Astley, M. A. McBurnie, K. Wentz, and A. L. Smith. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328:1740-1746.
292. Smith, A. L., G. Redding, C. Doershuk, D. Goldmann, E. Gore, B. Human, M. Marks, R. Moss, B. Ramsey, T. Rubio, R. H. Schwartz, M. J. Thomassen, J. Williams-Warren, A. Weber, R. W. Wilmott, H. D. Wilson, and R. Yogev. 1988. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J. Pediatr. 112:547-554.
293. Turpin, S. V., and M. R. Knowles. 1993. Treatment of pulmonary disease in patients with cystic fibrosis. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 277-344.
294. Pennington, J. E., H. Y. Reynolds, R. E. Wood, R. A. Robinson, and A. S. Levine. 1975. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am. J. Med. 58:629-635.
295. Wood, R. E., J. E. Pennington, and H. Y. Reynolds. 1983. Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients. Pediatr. Infect. Dis. 2:367-369.
296. Langford, D. T., and J. Hiller. 1984. Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis: three year results. Arch. Dis. Child 59:1131-1134.
297. Schaad, U. B., A. B. Lang, J. Wedgwood, A. Ruedeberg, J. U. Que, E. Furer, and S. J. J. Cryz. 1991. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 338:1236-1237.
298. Cryz, S. J., Jr., J. Wedgwood, A. B. Lang, A. Ruedeberg, J. U. Que, E. Furer, and U. B. Schaad. 1994. Immunization of noncolonized cystic fibosis patients against Pseudomonas aeruginosa. J. Infect. Dis. 169:1159-1162.
299. Winnie, G. B., R. G. Cowan, and N. A. Wade. 1989. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. J. Pediatr. 114:309-314.
300. Van Wye, J. E., M. S. Collins, M. Baylor, J. E. Pennington, Y. P. Hsu, V. Sampanvejsopa, and R. B. Moss. 1990. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 9:7-18.
301. Pier, G. B., G. J. Small, and H. B. Warren. 1990. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 249:537-540.
302. Moss, R., R. Fink, S. Schroeder, B. Ramsey, L. Fries, S. Fuller, S. Harkonen, L. Muenz, and M. Thornton. 1995. Safety and pharmacokinetics of a mucoid Pseudomonas aeruginosa immune globulin. Intravenous (human) in patients with cystic fibrosis-preliminary results of a phase I/II trial. Pediatr. Pulmonol. 19:85.
303. Wang, E. E. L., C. G. Prober, B. Manson, M. Corey, and H. Levison. 1984. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N. Engl. J. Med. 311:1653-1658.
304. Birrer, P., N. G. McElvaney, A. Rudeberg, C. W. Sommer, S. Liechti-Gallati, R. Kraemer, R. Hubbard, and R. G. Crystal. 1994. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 150:207-213.
305. Konstan, M. W., K. A. Hilliard, T. M. Norvell, and M. Berger. 1994. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am. J. Respir. Crit. Care Med. 150:448-454.
306. Cantin, A. 1995. Cystic fibrosis lung inflammation: early, sustained, and severe. Am. J. Respir. Crit. Care Med. 151:939-941.
307. Auerbach, H. S., M. Williams, J. A. Kirkpatrick, and H. R. Colten. 1985. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2:686-688.
308. Donati, M. A., K. Haver, W. Gerson, M. Klein, F. J. McLaughlin, and M. E. B. Wohl. 1990. Long-term alternate day prednisone therapy in cystic fibrosis. Pediatr. Pulmonol. Suppl. 5:277.
309. Eigen, H., B. J. Rosenstein, S. FitzSimmons, and D. V. Schidlow. 1995. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J. Pediatr. 126:515-523.
310. Rosenstein, B. J., and H. Eigen. 1991. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 87:245-246.
311. Greally, P., M. J. Hussain, D. Vergani, and J. F. Price. 1994. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch. Dis. Child. 71:35-39.
312. Schiotz, P. O., M. Jorgensen, E. W. Flensborg, O. Faero, S. Husby, N. Hoiby, S. V. Jacobsen, H. Nielsen, and S. E. Svehag. 1983. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr. Scand. 72:283-287.
313. Bisgaard, H., K. G. Nielsen, M. Skov, E. Mosfeldt, B. Bjerre, S. S. Pedersen, N. Hoiby, and C. Koch. 1994. Inhaled steroid treatment of CF patients with chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulmonol. Suppl. 10:289.
314. Nikolaizik, W. H., and M. H. Schöni. 1996. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J. Pediatr. 128:271-274.
315. Konstan, M. W., K. M. Vargo, and P. B. Davis. 1990. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis. Am. Rev. Respir. Dis. 141: 186-192.
316. Konstan, M. W., K. A. Hilliard, and P. B. Davis. 1989. Effect of ibuprofen on neutrophil delivery to mucosal surfaces. Pediatr. Pulmonol. Suppl. 4:152-153.
317. Konstan, M. W., C. L. Hoppel, B. Chai, and P. B. Davis. 1991. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J. Pediatr. 118:956-964.
318. Konstan, M. W., P. J. Byard, C. L. Hoppel, and P. B. Davis. 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332:848-854.
319. Sordelli, D. O., M. C. Cerquetti, P. A. Fontan, and R. P. Meiss. 1989. Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa. J. Infect. Dis. 159:232-238.
320. Sordelli, D. O., C. N. Macri, A. J. Maillie, and M. C. Cerquetti. 1994. A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Int. J. Immunopathol. Pharmacol. 7:109-117.
321. Cheung, A. T., R. B. Moss, G. Kurland, A. B. Leong, and W. J. Novick, Jr. 1993. Pseudomonas aeruginosa endobronchitis in rhesus monkeys: II. A histopathologic analysis. J. Med. Primatol. 22: 257-262.
322. Aronoff, S. C., F. J. Quinn, Jr., L. S. Carpenter, and W. J. Novick, Jr. 1994. Effects of pentoxifylline on sputum neutophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J. Pediatr. 125:992-997.
323. Henderson, W. R., Jr., S. J. Astley, M. M. McCready, P. Kushmerick, S. Casey, J. W. Becker, and B. W. Ramsey. 1994. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr. 124:400-408.
324. McElvaney, N. G., R. C. Hubbard, P. Birrer, M.S. Chernick, D. B. Caplan, M. M. Frank, and R. G. Crystal. 1991. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 337:392-394.
325. McElvaney, N. G., H. Nakamura, P. Birrer, C. A. Hebert, W. L. Wong, M. Alphonso, J. B. Baker, M. A. Catalano, and R. G. Crystal. 1992. Modulation of airway inflammation in cystic fibrosis: In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant seretory leukoprotease inhibitor. J. Clin. Invest. 90:1296-1301.
326. McElvaney, N. G., B. Doujaiji, M. J. Moan, M. R. Burnham, M. C. Wu, and R. G. Crystal. 1993. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis. 148:1056-1060.
327. Williams, J. C., R. C. Falcone, C. Knee, R. L. Stein, A. M. Strimpler, B. Reaves, R. E. Giles, and R. D. Krell. 1991. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am. Rev. Respir. Dis. 144:875-883.
328. Mumford, R., R. Chabin, S. Chiu, P. Davies, J. Doherty, P. Finke, D. Fletcher, B. Green, P. Griffen, A. Kissinger, W. Knight, M. Kostura, T. Klatt, M. MacCoss, R. Meurer, D. Miller, S. Pacholok, M. Poe, S. Shah, S. Vincent, H. Williams, and J. Humes. 1995. A cell-penetrant monocyclic β-lactam inhibitor which inactivates elastase within PMN in vitro and in vivo (abstract). Am. J. Respir. Crit. Care Med. 151:A532.
329. Schidlow, D. V., L. M. Taussig, and M. R. Knowles. 1993. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr. Pulmonol. 15:187-198.
330. Stern, R. C., G. Borkat, S. S. Hirchfeld, T. F. Boat, L. W. Matthews, J. Liebman, and C. F. Doershuk. 1980. Heart failure in cystic fibrosis: treatment and prognosis of cor pulmonale with failure of the right side of the heart. Am. J. Dis. Child. 134:267-272.
331. Holsclaw, D. S., R. J. Grand, and H. Schwachman. 1970. Massive hemoptysis in cystic fibrosis. J. Pediatr. 76:829-838.
332. Stern, R. C., R. E. Wood, T. F. Boat, L. W. Matthews, A. S. Tucker, and C. F. Doershuk. 1978. Treatment and progression of massive hemoptysis in cystic fibrosis. Am. Rev. Respir. Dis. 117:825-828.
333. Bilton, D., A. K. Webb, H. Foster, P. Mulvenna, and M. Dodd. 1990. Life threatening haemoptysis in cystic fibrosis: An alternative therapeutic approach. Thorax 45:975-976.
334. Cohen, A. M., C. F. Doershuk, and R. C. Stern. 1990. Bronchial artery embolization to control hemoptysis in cystic fibrosis. Radiology 175:401-403.
335. Fellows, K. E., K. T. Khaw, S. Schuster, and H. Shwachman. 1995. Bronchial artery embolization in cystic fibrosis; technique and long-term results. J. Pediatr. 95:959-963.
336. Porter, D. K., M. J. Van Every, and J. W. Mack. 1983. Emergency lobectomy for massive hemoptysis in cystic fibrosis. J. Thorac. Cardiovasc. Surg. 86:409-411.
337. Boat, T. F., P. A. di Sant'Agnese, W. J. Warwick, and S. A. Handwerger. 1969. Pneumothorax in cystic fibrosis. J.A.M.A. 209: 1498-1504.
338. Lifschitz, M. I., F. O. Bowman, Jr., C. R. Denning, and R. H. Wylie. 1968. Pneumothorax as a complication of cystic fibrosis: report of twenty cases. Am. J. Dis. Child 116:633-640.
339. Stowe, S. M., T. F. Boat, H. Mendelsohn, R. C. Stern, A. S. Tucker, C. F. Doershuk, and L. W. Matthews. 1975. Open thoracotomy for pneumothorax in cystic fibrosis. Am. Rev. Respir. Dis. 111:611-617.
340. McLaughlin, F. J., W. J. Matthews, Jr., D. J. Strieder, K. T. Khaw, S. Schuster, and H. Shwachman. 1982. Pneumothorax in cystic fibrosis: management and outcome. J. Pediatr. 100:863-869.
341. Tomashefski, J. F., Jr., M. Bruce, R. C. Stern, D. G. Dearborn, and B. Dahms. 1985. Pulmonary air cysts in cystic fibrosis: relation of pathologic features to radiologic findings and history of pneumothorax. Hum. Pathol. 16:253-261.
342. Spector, M. L., and R. C. Stern. 1989. Pneumothorax in cystic fibrosis: a 26-year experience. Ann. Thorac. Surg. 47:204-207.
343. Noyes, B. E., and D. M. Orenstein. 1992. Treatment of pneumothorax in cystic fibrosis in the era of lung transplantation. Chest 101: 1187-1188.
344. Cohen, A. M., B. S. Yulish, K. B. Wasser, P. J. Vignos, P. K. Jones, and S. B. Sorin. 1986. Evaluation of pulmonary hypertrophie osteoarthropathy in cystic fibrosis. Am. J. Dis. Child. 140:74-77.
345. Dixey, J., A. N. Redington, R. C. Butler, M. J. Smith, J. R. Batchelor, D. F. Woodrow, M. E. Hodson, J. C. Batten, and D. A. Brewerton. 1988. The arthropathy of cystic fibrosis. Ann. Rheum. Dis. 47:218-223.
346. Neuman, A. J., and B. M. Ansell. 1979. Episodic arthritis in children with cystic fibrosis. J. Pediatr. 94:594-596.
347. Wulffraat, N. M., E. R. de Graeff Meeder, G. T. Rijkers, H. van der Laag, and W. Kuis. 1994. Prevalence of circulating immune complexes in patients with cystic fibrosis and arthritis. J. Pediatr. 125: 374-378.
348. Lawrence, J. M., III, T. L. Moore, K. L. Madson, A. J. Rejent, and T. G. Osborn. 1993. Arthropathies of cystic fibrosis: case reports and review of the literature. J. Rheumatol. 20(Suppl. 38):12-15.
349. Hodson, M. E. 1992. Vasculitis and arthropathy in cystic fibrosis. J. R. Soc. Med. 85(Suppl. 19):38-40.
350. Egan, T. M., F. C. Detterbeck, M. R. Mill, L. J. Paradowski, R. P. Lackner, W. D. Ogden, J. R. Yankaskas, J. H. Westerman, J. T. Thompson, M. A. Weiner, E. L. Cairns, and B. R. Wilcox. 1995. Improved results of lung transplantation for patients with cystic fibrosis. J. Thorac. Cardiovasc. Surg. 109:224-234.
351. Egan, T. M. 1992. Lung transplantation in cystic fibrosis. Semin. Respir. Infect. 7:227-239.
352. Shennib, H., R. Adoumie, and H. Noirclerc. 1992. Current status of lung transplantation for cystic fibrosis. Arch. Intern. Med. 152: 1585-1588.
353. Smyth, R. L., T. Higenbottam, J. Scott, and J. Wallwork. 1991. Cystic fibrosis. 5. The current state of lung transplantation for cystic fibrosis. Thorax 46:213-216.
354. Tsang, V., M. E. Hodson, and M. H. Yacoub. 1992. Lung transplantation for cystic fibrosis. Br. Med. Bull. 48:949-971.
355. Davis, P. B., and P. A. di Sant'Agnese. 1978. Assisted ventilation for patients with cystic fibrosis. J.A.M.A. 239:1851-1854.
356. Hodson, M. E., B. P. Madden, M. H. Steven, V. T. Tsang, and M. H. Yacoub. 1991. Noninvasive mechanical ventilation for cystic fibrosis patients: a potential bridge to transplantation. Eur. Respir. J. 4:524-527.
357. Johnson, L. G., J. C. Olsen, B. Sarkadi, K. L. Moore, R. Swanstrom, and R. C. Boucher. 1992. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2:21-25.
358. Grubb, B. R., R. J. Pickles, H. Ye, J. R. Yankaskas, R. N. Vick, J. F. Engelhardt, J. M. Wilson, L. G. Johnson, and R. C. Boucher. 1994. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelial of mice and humans. Nature 371:802-806.
359. Knowles, M. R., K. W. Hohneker, Z. Q. Zhou, J. C. Olsen, T. L. Noah, P. C. Hu, M. W. Leigh, J. F. Engelhardt, L. J. Edwards, K. R. Jones, M. Grossman, J. M. Wilson, L. G. Johnson, and R. C. Boucher. 1995. A controlled study of adenoviral-vector-medicated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333:823-831.
360. Zabner, J., L. A. Couture, R. J. Gregory, S. M. Graham, A. E. Smith, and M. J. Welsh. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207-216.
361. Yei, S., N. Mittereder, K. Tang, C. O'Sullivan, and B. C. Trapnell. 1994. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therap. 1:192-200.
362. Crystal, R. G., N. G. McElvaney, M. A. Rosenfeld, C.-S. Chu, A. Mastrangeli, J. G. Hay, S. L. Brody, H. A. Jaffe, N. T. Eissa, and C. Danel. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-51.
363. Yang, Y., F. A. Nunes, K. Berencsi, E. Gönczöl, J. R. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369.
364. Yang, Y., G. Trinchieri, and J. M. Wilson. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1:890-893.
365. Flotte, T. R., S. A. Afione, C. Conrad, S. A. McGrath, R. Solow, H. Oka, P. L. Zeitlin, W. B. Guggino, and B. J. Carter. 1993. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. U.S.A. 90:10613-10617.
366. Flotte, T. R., S. A. Afione, R. Solow, M. L. Drumm, D. Markakis, W. B. Guggino, P. L. Zeitlin, and B. J. Carter. 1993. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268:3781-3790.
367. Flotte, T. R., R. Solow, R. A. Owens, S. Afione, P. L. Zeitlin, and B. J. Carter. 1992. Gene expression from adeno-associated virus vectors in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 7: 349-356.
368. Alton, E. W. F. W., P. G. Middleton, N. J. Caplen, S. N. Smith, D. M. Steel, F. M. Munkonge, P. K. Jeffery, S. L. Hart, R. Williamson, K. I. Fasold, A. D. Miller, P. Dickinson, B. J. Stevenson, G. McLachlan, J. R. Dorin, and D. I. Porteous. 1993. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat. Genet. 5:135-142.
369. Hyde, S. C., D. R. Gill, C. F. Higgins, and Ann E. O. Trezise. 1993. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362:250-255.
370. Caplen, N. J., E. F. W. Alton, P. G. Middleton, J. P. Dorin, B. I. Stevenson, X. Gao, S. R. Durham, P. K. Jeffrey, M. E. Hodson, C. Contelle, L. Huang, D. J. Portcons, R. Williamson, and D. M. Geddes. 1995. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1:39-46.
371. Marshall, J., E. Lee, J. Nietupski, C. Siegel, M. Nichols, P. Rafter, M. Cherry, J. M. Kaplan, J. A. St. George, D. Garlick, C. Jiang, N. S. Yew, R. K. Scheule, D. Harris, A. E. Smith, and S. H. Cheng. 1995. Development and use of novel synthetic cationic lipids with enhanced gene transfer activity. Pediatr. Pulmonol. Suppl. 12:216.
372. Ferkol, T., J. C. Perales, E. Eckman, C. S. Kaetzel, R. W. Hanson, and P. B. Davis. 1995. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 95:493-502.
373. Englehardt, J. F., J. R. Yankaskas, S. A. Ernst, Y. Yang, C. R. Marino, R. C. Boucher, J. A. Cohn, and J. M. Wilson. 1992. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat. Genet. 2:240-247.
374. Johsnon, L. G., S. E. Boyles, J. Wilson, and R. C. Boucher. 1995. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J. Clin. Invest. 95:1377-1382.
375. Goldman, M. J., Y. Yang, and J. M. Wilson. 1995. Gene therapy in xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nat. Genet. 9:126-131.
376. Scheule, R. K., R. G. Bagley, A. L. Erickson, K. X. Wang, S. L. Fang, C. Vaccaro, C. R. O'Riordan, S. H. Cheng, and A. E. Smith. 1995. Delivery of purified, functional CFTR to epithelial cells in vitro using influenza hemagglutinin. Am. J. Respir. Cell Mol. Biol. 13:330-343.
377. Eidelman, O., C. Guay Broder, P. J. van Galen, K. A. Jacobson, C. Fox, R. J. Turner, Z. I. Cabantchik, and H. B. Pollard. 1992. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. U.S.A. 89:5562-5566.
378. Gribkoff, V. K., O. Champigny, P. Barbry, S. I. Dworetzky, N. A. Meanwell, and M. Lazdunski. 1994. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. 269:10983-10986.
379. Graham, A., A. Hasani, E. W. F. W. Alton, G. P. Martin, C. Marriott, M. E. Hodson, S. W. Clarke, and D. M. Geddes. 1993. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J. 6:1243-1248.
380. Davis, P. B. 1995. Saturday's children. Am. J. Respir. Crit. Care Med. 152:1-2.